Adam focuses his practice on corporate law, financing, and technology transactions in the life sciences and health technology industries. His clients include a wide range of life science and health care companies, as well as venture capital and private equity funds.
Adam has a specific focus on strategic partnering and commercialization for pharmaceutical, biotechnology, and medical device companies. He frequently advises on complex licensing, strategic collaborations, venture capital, mergers and acquisitions, and intellectual property transactions and helps his clients develop, scale, and commercialize their technologies in Canada, the United States, and other countries around the world.
Before law school, Adam attended the Leslie Dan Faculty of Pharmacy at the University of Toronto and is a licensed pharmacist in Ontario.
News & Press
Mintz Associate Adam Falconi has been appointed Chair of Life Sciences for Licensing Executives Society (USA & Canada), Inc. (LES).
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.
Mintz Recognized in LMG’s “Life Sciences Americas Awards” 2024
September 06, 2024
Mintz received two awards at LMG’s 2024 “Life Sciences Americas Awards” which recognize the region’s “most distinguished practitioners and their firms for their exemplary work in the Life Sciences legal practice over the past twelve months.” The firm earned the “Impact Deal of the Year” for its role advising on a joint venture between ITM Isotope Technologies Munich SE (ITM) and Canadian Nuclear Laboratories (CNL), while Associate Adam Falconi was named a “Canada Rising Star.”
Mintz Shortlisted for LMG Life Sciences Awards 2024 Americas
August 22, 2024
Mintz’s cross-border Life Sciences practice has been shortlisted in multiple categories in the LMG Life Sciences Awards 2024 Americas. Winners will be announced on September 5th.
Six Mintz Attorneys Ranked In Chambers Canada
September 28, 2023
TORONTO – Mintz announced today that six attorneys have been ranked in the 2024 edition of Chambers Canada, marking the first time the firm has been included in the guide.
Events & Speaking
Life Sciences Spinouts from In-License to Exit – Key Issues for Success
Licensing Executives Society (LES) Annual Meeting
New Orleans
Doing Life Sciences Deals in 2024 - Licensing, M&A, and More
Hosted by Mintz and the Life Sciences Sector and the Boston Chapter of Licensing Executives Society USA and Canada
Boston
Strategies for New Ventures in a Dynamic Environment Facing Today's Geopolitical Realities
AUTM Annual Meeting
Biotech Licenses in the 2020s – Everything You Need to Know About Cell and Gene Therapy Licenses
Licensing Executives Society Annual Meeting
Chicago, IL
Recognition & Awards
Chambers Canada: Life Sciences: Corporate/Commercial Nationwide, Associates to Watch
Canadian Rising Star, LMG Life Sciences Americas Awards (2024)
Involvement
- Chair, Life Sciences Sector of the Licensing Executives Society (LES)
- Chair, Medical Devices Committee of the Licensing Executives Society (LES)
- Certified Licensing Professional (CLP)
- Member, Ontario College of Pharmacists
Recent Insights
Mintz Associate Adam Falconi has been appointed Chair of Life Sciences for Licensing Executives Society (USA & Canada), Inc. (LES).
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.
Mintz received two awards at LMG’s 2024 “Life Sciences Americas Awards” which recognize the region’s “most distinguished practitioners and their firms for their exemplary work in the Life Sciences legal practice over the past twelve months.” The firm earned the “Impact Deal of the Year” for its role advising on a joint venture between ITM Isotope Technologies Munich SE (ITM) and Canadian Nuclear Laboratories (CNL), while Associate Adam Falconi was named a “Canada Rising Star.”
